Drug Pricing: National Academies Weighs In With Some Familiar Proposals
Government price negotiations, financial transparency in the drug supply chain and changes to orphan drug incentives would go a long way toward making drugs more affordable, a National Academies committee says in a new report; dissent authored by two pharma industry veterans warns of 'unintended consequences' if recommendations are implemented.
You may also be interested in...
Policymakers should instead focus on increasing efficiencies in drug development, distribution and reimbursement, National Academies report says, while also seeking broad policies like HHS direct negotiation for drug prices in Medicare.
Some patient groups, payers support CMS proposal to require disclosure of list prices in TV ads but want to expand the requirement to other media and beef up enforcement. Others are skeptical the proposal would lower prices.
FDA is planning series of stakeholder meetings to identify new approaches to drug shortages, with particular interest in defining “essential” drugs. Agency is also looking outside for expertise, with Boston University’s Rena Conti tapped as advisor.